Yıl: 2021 Cilt: 31 Sayı: 1 Sayfa Aralığı: 60 - 66 Metin Dili: İngilizce DOI: 10.5152/pcp.2021.20175 İndeks Tarihi: 10-05-2023

The Prevalence of Sarcopenia in Patients with Schizophrenia

Öz:
Objective: In this study, we aimed to investigate the frequency of sarcopenia in patients with schizophrenia and the risk factors that may be associated with sarcopenia. Methods: We recruited 72 schizophrenia patients who had registered in the schizophrenia specialized unit of Çukurova University. The socio-demographic variable form was filled. Each patient underwent physical mass, strength, and performance tests to confirm the diagnosis of sarcopenia (SP), which was made according to the criteria of European Consensus. Results: Mean age of the patients was 39.50 (19-65) years for the possible sarcopenia group and 37.00 (21-65) years for without SP group. Possible sarcopenia was 36.1% (n=26), and SP and severe SP were 0.0% in schizophrenia patients. Total body water (TBW) (37.60 vs. 43.90) and bone mineral density (2.70 vs. 3.10) values were significantly lower in the possible SP group compared to the non-sarcopenia group (P=.011 and P=.025, respectively). However, it was found that muscle mass (kg) (51.05 vs. 58.65) and muscle strength (kg/kg) (20.70 vs. 33.15) were significantly lower in the possible SP group compared to the non-sarcopenia group (P=.042 and P=.001, respectively). Compared to the non sarcopenia group, patient exercising was less in the possible SP group (4 vs. 9, P=.001), while walking speeds (m/s) were statistically faster in the possible SP group (6.74 vs. 5.98, P=.010). Conclusion: This is the first study that investigated SP in schizophrenia patients. Sarcopenia was found more frequently in schizophrenia patients than in the general population
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Dişcigil G, Sökmen ÜN. Yaşlılıkta sarkopeni. J Turk Fam Phys. 2017;8(2):49-54. [CrossRef]
  • 2. Yaman HY, Vural RV. Management of sarcopenia in elderlies. TJFMPC. 2016;10(4):243-249. [CrossRef]
  • 3. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. [CrossRef]
  • 4. Walston JD. Sarcopenia in older adults. Curr Opin Rheumatol. 2012;24(6):623-627. [CrossRef]
  • 5. Bautmans I, Van Puyvelde K, Mets T. Sarcopenia and functional decline: pathophysiology, prevention and therapy. Acta Clin Belg. 2009;64(4):303-316. [CrossRef]
  • 6. Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43(6):748- 759. [CrossRef]
  • 7. An KO, Kim J. Association of sarcopenia and obesity with multimorbidity in Korean adults: a nationwide cross sectional study. J Am Med Dir Assoc. 2016;17(10):960. e1-960.e7. [CrossRef]
  • 8. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-423. [CrossRef]
  • 9. Kuyumcu ME, Halil M, Kara Ö, et al. Ultrasonographic evaluation of the calf muscle mass and architecture in elderly patients with and without sarcopenia. Arch Gerontol Geriatr Gerontol Int. 2016;65:218-224. [CrossRef]
  • 10. Patel HP, Syddall HE, Jameson K, et al. Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing. 2013;42(3):378-384. [CrossRef]
  • 11. Sayer AA, Syddall HE, Martin HJ, et al. Is grip strength associated with health-related quality of life? Findings from the Hertfordshire Cohort Study. Age Ageing. 2006;35(4):409-415. [CrossRef]
  • 12. Savaş S. Sarkopeniden korunma. Ege J Med. 2015;54(suppl):46-50. [CrossRef]
  • 13. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295-301. [CrossRef]
  • 14. Jin H, Mosweu I. The societal cost of schizophrenia: a systematic review. Pharmacoeconomics. 2017;35(1):25- 42. [CrossRef]
  • 15. Laursen TM, Wahlbeck K, Hällgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the Nordic countries. PLoS One. 2013;8(6):e67133. [CrossRef]
  • 16. Harvey PD, Rosenthal JB. Cognitive and functional deficits in people with schizophrenia: evidence for accelerated or exaggerated aging? Schizophr Res. 2018;196:14-21. [CrossRef]
  • 17. Scheewe TW, Takken T, Kahn RS, Cahn W, Backx FJ. Effects of exercise therapy on cardiorespiratory fitness in patients with schizophrenia. Med Sci Sports Exerc. 2012;44(10):1834-1842. [CrossRef]
  • 18. Strassnig M, Brar JS, Ganguli R. Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. Schizophr Res. 2011;126(1-3):103- 109. [CrossRef]
  • 19. Vancampfort D, Probst M, Scheewe T, et al. The functional exercise capacity is correlated with global functioning in patients with schizophrenia. Acta Psychiatr Scand. 2012;125(5):382-387. [CrossRef]
  • 20. Vancampfort D, Probst M, Sweers K, et al. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia. Acta Psychiatr Scand. 2011;123(6):423-430. [CrossRef]
  • 21. Martín-Sierra A, Vancampfort D, Probst M, et al. Walking capacity is associated with health related quality of life and physical activity level in patients with schizophrenia: a preliminary report. Actas Esp Psiquiatr. 2011;39(4):211- 216. https://www.ncbi.nlm.nih.gov/pubmed/21769744.
  • 22. Pasco JA. Age-related changes in muscle and bone. In: Duque G, ed., Osteosarcopenia: Bone, Muscle and Fat Interactions. Cham: Springer; 2019:45-71. [CrossRef]
  • 23. Nygård M, Brobakken MF, Roel RB, et al. Patients with schizophrenia have impaired muscle force-generating capacity and functional performance. Scand J Med Sci Sports. 2019;29(12):1968-1979. [CrossRef]
  • 24. Morris G, Walder KR, Berk M, et al. The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it? Mol Biol Rep. 2020;47(7):5587-5620. [CrossRef]
  • 25. Bulbul F, Koca I, Tamam L, et al. The prevalence of sarcopenia in bipolar disorder. Neuropsychiatr Dis Treat. 2020;16:915-921. [CrossRef]
  • 26. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-191. [CrossRef]
  • 27. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000;89(2):465-471. [CrossRef]
  • 28. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002;57(12):M772-M777. [CrossRef]
  • 29. Bahat G, Tufan A, Tufan F, et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr. 2016;35(6):1557-1563. [CrossRef]
  • 30. Massy-Westropp NM, Gill TK, Taylor AW, Bohannon RW, Hill CL. Hand grip strength: age and gender stratified normative data in a population-based study. BMC Res Notes. 2011;4:127. [CrossRef]
  • 31. Mathiowetz V. Comparison of Rolyan and Jamar dynamometers for measuring grip strength. Occup Ther Int. 2002;9(3):201-209. [CrossRef]
  • 32. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80-85. [CrossRef]
  • 33. Walrand S, Guillet C, Salles J, Cano N, Boirie Y. Physiopathological mechanism of sarcopenia. Clin Geriatr Med. 2011;27(3):365-385. [CrossRef]
  • 34. Morley JE. Sarcopenia: diagnosis and treatment. J Nutr Health Aging. 2008;12(7):452-456. [CrossRef]
  • 35. Van Kan GA. Epidemiology and consequences of sarcopenia. J Nutr Health Aging. 2009;13(8):708-712. [CrossRef]
  • 36. Krzymińska-Siemaszko R, Fryzowicz A, Czepulis N, et al. The impact of the age range of young healthy reference population on the cut-off points for low muscle mass necessary for the diagnosis of sarcopenia. Eur Rev Med Pharmacol Sci. 2019;23(10):4321-4332. [CrossRef]
  • 37. Öztürk ZA, Türkbeyler İH, Abiyev A, et al. Health related quality of life and fall risk associated with age related body composition changes; sarcopenia, obesity and sarcopenic obesity. Intern Med J. 2018;48(8):973-981. [CrossRef]
  • 38. de Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77. [CrossRef]
  • 39. Vancampfort D, Sweers K, Probst M, et al. Quality assessment of physical activity recommendations within clinical practice guidelines for the prevention and treatment of cardio-metabolic risk factors in people with schizophrenia. Commun Ment Health J. 2011;47(6):703- 710. [CrossRef]
  • 40. Vancampfort D, Stubbs B, Sienaert P, et al. A comparison of physical fitness in patients with bipolar disorder, schizophrenia and healthy controls. Disabil Rehabil. 2016;38(20):2047-2051. [CrossRef]
  • 41. Pasco JA, Williams LJ, Jacka FN, et al. Sarcopenia and the common mental disorders: a potential regulatory role of skeletal muscle on brain function? Curr Osteoporos Rep. 2015;13(5):351-357. [CrossRef]
  • 42. Can B, Kara O, Kizilarslanoglu MC, et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res. 2017;29(4):745-752. [CrossRef]
  • 43. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 2010;11(4):1509-1526. [CrossRef]
  • 44. Ramírez-Jirano LJ, Velasco-Ramírez SF, Pérez Carranza GA, Domínguez-Díaz C, Bitzer-Quintero OK. Cytokines and nervous system: relationship with schizophrenia. Rev Med Inst Mex Seguro Soc. 2019;57(2):107-112. [CrossRef]
  • 45. Tondo L, Vázquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Curr Neuropharmacol. 2017;15(3):353-358. [CrossRef]
  • 46. Vancampfort D, Sienaert P, Wyckaert S, et al. Health related physical fitness in patients with bipolar disorder vs. healthy controls: an exploratory study. J Affect Disord. 2015;177:22-27. [CrossRef]
  • 47. Akishita M, Kozaki K, Iijima K, et al. Chapter 1 Definitions and diagnosis of sarcopenia. Geriatr Gerontol Int. 2018. Chapter 1;18(suppl 1):7-12. [CrossRef]
  • 48. Buch A, Carmeli E, Boker LK, et al. Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age-an overview. Exp Gerontol. 2016;76:25-32. [CrossRef]
  • 49. Gurholt TP, Haukvik UK, Lonning V, et al. Microstructural white matter and links with subcortical structures in chronic schizophrenia: a free-water imaging approach. Front Psychiatry. 2020;11:56. [CrossRef]
APA Bülbül F, Tamam L, Demirkol M, çakmak s, namlı z, Erşahinoğlu E (2021). The Prevalence of Sarcopenia in Patients with Schizophrenia. , 60 - 66. 10.5152/pcp.2021.20175
Chicago Bülbül Feridun,Tamam Lut,Demirkol Mehmet Emin,çakmak soner,namlı zeynep,Erşahinoğlu Emre The Prevalence of Sarcopenia in Patients with Schizophrenia. (2021): 60 - 66. 10.5152/pcp.2021.20175
MLA Bülbül Feridun,Tamam Lut,Demirkol Mehmet Emin,çakmak soner,namlı zeynep,Erşahinoğlu Emre The Prevalence of Sarcopenia in Patients with Schizophrenia. , 2021, ss.60 - 66. 10.5152/pcp.2021.20175
AMA Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E The Prevalence of Sarcopenia in Patients with Schizophrenia. . 2021; 60 - 66. 10.5152/pcp.2021.20175
Vancouver Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E The Prevalence of Sarcopenia in Patients with Schizophrenia. . 2021; 60 - 66. 10.5152/pcp.2021.20175
IEEE Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E "The Prevalence of Sarcopenia in Patients with Schizophrenia." , ss.60 - 66, 2021. 10.5152/pcp.2021.20175
ISNAD Bülbül, Feridun vd. "The Prevalence of Sarcopenia in Patients with Schizophrenia". (2021), 60-66. https://doi.org/10.5152/pcp.2021.20175
APA Bülbül F, Tamam L, Demirkol M, çakmak s, namlı z, Erşahinoğlu E (2021). The Prevalence of Sarcopenia in Patients with Schizophrenia. Psychiatry and clinical psychopharmacology (Online), 31(1), 60 - 66. 10.5152/pcp.2021.20175
Chicago Bülbül Feridun,Tamam Lut,Demirkol Mehmet Emin,çakmak soner,namlı zeynep,Erşahinoğlu Emre The Prevalence of Sarcopenia in Patients with Schizophrenia. Psychiatry and clinical psychopharmacology (Online) 31, no.1 (2021): 60 - 66. 10.5152/pcp.2021.20175
MLA Bülbül Feridun,Tamam Lut,Demirkol Mehmet Emin,çakmak soner,namlı zeynep,Erşahinoğlu Emre The Prevalence of Sarcopenia in Patients with Schizophrenia. Psychiatry and clinical psychopharmacology (Online), vol.31, no.1, 2021, ss.60 - 66. 10.5152/pcp.2021.20175
AMA Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E The Prevalence of Sarcopenia in Patients with Schizophrenia. Psychiatry and clinical psychopharmacology (Online). 2021; 31(1): 60 - 66. 10.5152/pcp.2021.20175
Vancouver Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E The Prevalence of Sarcopenia in Patients with Schizophrenia. Psychiatry and clinical psychopharmacology (Online). 2021; 31(1): 60 - 66. 10.5152/pcp.2021.20175
IEEE Bülbül F,Tamam L,Demirkol M,çakmak s,namlı z,Erşahinoğlu E "The Prevalence of Sarcopenia in Patients with Schizophrenia." Psychiatry and clinical psychopharmacology (Online), 31, ss.60 - 66, 2021. 10.5152/pcp.2021.20175
ISNAD Bülbül, Feridun vd. "The Prevalence of Sarcopenia in Patients with Schizophrenia". Psychiatry and clinical psychopharmacology (Online) 31/1 (2021), 60-66. https://doi.org/10.5152/pcp.2021.20175